Lexaria Bioscience Corp. (LEXX) stock
LEXXNasdaqPharmaceutical PreparationsFiscal year ends August 31
$4.44+0.26 (+6.22%)
Close on Nov 13, 2026Market cap $110.06MP/E –Yield –
Lexaria Bioscience ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Lexaria Bioscience's ebitda for the twelve months ending May 31, 2026 was -$7.68M. For fiscal 2025 it was -$11.83M. The highest annual figure on record is -$5.58M in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | -$11.83M | – |
| FY2024 | Aug 31, 2024 | -$5.71M | – |
| FY2023 | Aug 31, 2023 | -$6.39M | – |
| FY2022 | Aug 31, 2022 | -$6.52M | – |
| FY2021 | Aug 31, 2021 | -$5.58M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | May 31, 2026 | -$1.98M | – |
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | -$1.44M | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | -$1.56M | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | -$2.70M | – |
| Q3 FY2025CQ2 2025 | May 31, 2025 | -$3.72M | – |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | -$2.75M | – |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | -$2.66M | – |
| Q4 FY2024CQ3 2024 | Aug 31, 2024 | -$2.22M | – |
| Q3 FY2024CQ2 2024 | May 31, 2024 | -$1.73M | – |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | -$652.07K | – |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | -$1.11M | – |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | -$1.04M | – |
| Q3 FY2023CQ2 2023 | May 31, 2023 | -$2.38M | – |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | -$1.30M | – |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | -$1.67M | – |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | -$723.82K | – |
| Q3 FY2022CQ2 2022 | May 31, 2022 | -$2.39M | – |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | -$1.27M | – |
See a number that looks wrong?